Original citation:

Permanent WRAP url:
http://wrap.warwick.ac.uk/65650

Copyright and reuse:
The Warwick Research Archive Portal (WRAP) makes this work of researchers of the University of Warwick available open access under the following conditions.

This article is made available under the Creative Commons Attribution- 3.0 Unported (CC BY 3.0) license and may be reused according to the conditions of the license. For more details see http://creativecommons.org/licenses/by/3.0/

A note on versions:
The version presented in WRAP is the published version, or, version of record, and may be cited as it appears here.

For more information, please contact the WRAP Team at: publications@warwick.ac.uk
Mirror-Image Organometallic Osmium Arene Iminopyridine Halido Complexes Exhibit Similar Potent Anticancer Activity


Abstract: Four chiral OsIII arene anticancer complexes have been isolated by fractional crystallization. The two iodo complexes, \((\text{Os}(\eta^2-p\text{-cym})(\text{ImpyMe})\text{Cl})\text{PF}_6\) \(\text{I}\) and \((\text{R}_{\text{Os}}\text{R}_p\text{C})\text{-}[\text{Os}(\eta^2-p\text{-cym})(\text{ImpyMe})\text{Cl})\text{PF}_6\) \(\text{II}\), share surprisingly similar cancer cell selectivity patterns with the anti-microtubule drug, vinblastine sulfate. However, no direct effect on tubulin polymerization was found for \(\text{I}\) and \(\text{II}\), an observation that appears to indicate a novel mechanism of action. In addition, complexes \(\text{I}\) and \(\text{II}\) demonstrated potential as transfer-hydrogenation catalysts for imine reduction.

Introduction

The U.S. Food and Drug Administration (FDA) has defined strict rules for the development of new stereoisomeric drugs, especially following the tragedy of severe birth defects caused by the \(S\) isomer of thalidomide \([1]\) (originally developed as an antisedative drug, then found to be an inhibitor of angiogenesis for anticancer treatment \([2,3]\)). The fast-growing field of bioorganometallic chemistry has attracted much interest in the development of the next generation of anticancer agents following the success of the platinum-based drugs cisplatin, carboplatin, and oxaliplatin \([4–8]\).

Examples ininclude ruthenium and osmium organometallic complexes that show promising anticancer activity. \([9–18]\) Notably, a number of these organometallic complexes contain chiral metal centers \([13–18]\). Although there are no preclinical or clinical reports of different activity of specific stereoisomers of an organometallic complex, it is of interest to investigate the possible role of stereochemistry in the biological activity for this class of compounds. In particular, the design of metal-based anticancer agents now also includes those interacting with protein targets, a fact that requires careful control of the chirality on the metal center \([19,20]\). For example, the chirality of a ruthenium center has been shown to affect the inhibition of glycogen synthase kinase 3 \([21]\). However, such studies are scarce, probably owing to the difficulty of isolating enantiomers or diastereomers of organometallic complexes \([22,23]\).

The first examples of organometallic complexes isolated with defined chiral metal centers appear to be those reported in 1969 by Brunner \([24]\): \([\text{Mn}(\eta^2-C_5H_5)(\text{CO})(\text{NO})(\text{Ph}_3\text{P})]\) \((\text{M} = \text{Cr, Mo, W})\) and \([\text{Mn}(\eta^2-C_5H_5)(\text{CO})(\text{NO})(\text{Ph}_3\text{P})]\) \([25]\). These complexes are all configurationally stable in the solid state. The configurational stability of the metal center in solution depends on the monodentate ligand; for example, \((\text{R}_{\text{Mn}}\text{R}_p\text{C})\text{-}[\text{Mn}(\eta^2-C_5H_5)(\text{CO})(\text{NO})(\text{Ph}_3\text{P})]\) \(\text{PF}_6\) are configurationally stable, whereas \((\text{R}_{\text{Mn}}\text{R}_p\text{C})\text{-}[\text{Mn}(\eta^2-C_5H_5)(\text{CO})(\text{NO})(\text{Ph}_3\text{P})]\) \(\text{PF}_6\) \((\text{R} = \text{acyl})\) can epimerize \([25]\).

Other factors involved in the configurational lability at the metal center in solution, such as temperature, solvent, or structural features, have been analyzed for diastereomeric RuIII organometallic arene com-
complexes\textsuperscript{[26–28]} but fewer studies have been carried out on epimerization of Os\textsuperscript{II} arene diastereomers.\textsuperscript{[29]} Examples of enantiopure half-sandwich anticancer complexes are scarce in the literature.\textsuperscript{[30,33]} In particular, the biological properties of pure epimers of chiral-at-osmium arene complexes have not been reported to date.

Os\textsuperscript{II},\textsuperscript{[32–34]} Os\textsuperscript{III}\textsuperscript{[35]} Os\textsuperscript{IV}\textsuperscript{[36]} and Os\textsuperscript{VI}\textsuperscript{[37]} complexes have been reported to show promising anticancer activity in recent years. Half-sandwich Os\textsuperscript{II} organometallic arene anticancer complexes containing a monodentate ligand and an unsymmetrical chelating ligand are chiral. Previously, we reported that the synthesis of the anticancer Os\textsuperscript{II} arene iminopyridine (Impy) complex, [Os(η\textsuperscript{4}-p-cym)(Impy-OH)]PF\textsubscript{6} (p-cym = para-cymene, Impy-OH = 4-[2-(pyridinylmethylene)aminophenol], gives a mixture of enantiomers in approximately 1:1 ratio.\textsuperscript{[14]} The enantiomeric resolution of such organometallic arene complexes would also be interesting in terms of elucidating mechanisms of action. Nevertheless, the purification of chiral osmium isomers is not easily achieved as chiral columns often produce low yields, and selective chiral synthesis on a metal center is still not readily achievable. Introduction of a chiral carbon atom into the chelated iminopyridine ligand of Os\textsuperscript{II} arene complexes has allowed a facile separation by fractional crystallization of the resulting diastereomeric complexes, which have different physical properties.

Organometallic arene iminopyridine complexes containing ruthenium\textsuperscript{[38,39]} and iridium\textsuperscript{[40]} can also act as transfer-hydrogenation catalysts. Catalytic transfer hydrogenation is a useful method for the preparation of amines of biological and chemical interest.\textsuperscript{[41]} The herein-reported Os\textsuperscript{II} arene diastereomers could be also attractive as asymmetric catalysts. There are very few reports on the catalytic potential of Os\textsuperscript{II} arene complexes as transfer-hydrogenation catalysts for imine reduction.\textsuperscript{[42,43]} Thus, the four Os\textsuperscript{II} arene iminopyridine complexes were also investigated as transfer-hydrogenation catalysts\textsuperscript{[42,43]} using a model imine substrate.

**Results**

The pure chiral iminopyridine ligand ((S)- or (R)-ImpyMe: N-(2-pyridylmethylene)-(S)-1-phenylethylamine or N-(2-pyridylmethylene)-(R)-1-phenylethylamine) was reacted with the Os\textsuperscript{II} dimer—[[Os(η\textsuperscript{4}-p-cym)Cl\textsubscript{2}]\textsubscript{2}] or [[Os(η\textsuperscript{4}-p-cym)I\textsubscript{2}]\textsubscript{2}]—to form both diastereomers; the diastereomer that crystallized first was collected from each reaction and the second diastereomer was left in the mother liquor. Only isolated single crystals were used for the physical and biological studies of all the four osmium complexes reported in this work. Although this approach to the study of chirality has been widely used on Ru\textsuperscript{II} and Os\textsuperscript{II} arene catalysts with “piano-stool” geometry, there appears to be no report of any application in metallo-drug research. This approach could pave the way for further investigations on the effect of chirality of osmium metal centers on their pharmacological behavior, including metabolism, toxicity, tissue distribution, and excretion kinetics.\textsuperscript{[44]}

**Synthesis and characterization:** Two asymmetric imine ligands (S)- and (R)-ImpyMe containing a chiral carbon atom were synthesized by condensation of 2-pyridine carboxaldehyde with (S)-(−)-α-methylbenzylamine or (R)-(+)α-methylbenzylamine and were purified by distillation by following a reported method.\textsuperscript{[45]} Four Os\textsuperscript{II} arene iminopyridine complexes of general formula [Os(η\textsuperscript{4}-p-cym)(ImpyMe)X\textsubscript{2}]PF\textsubscript{6} (X = Cl, I) were synthesized by reaction of the corresponding dimer —[[Os(η\textsuperscript{4}-p-cym)X\textsubscript{2}]\textsubscript{2}] (X = Cl, I) and the chiral ligands (S)- or (R)-ImpyMe as described in the Experimental Section. As the chiral configuration of each enantiopure ligand is retained in solution, the Os\textsuperscript{II} arene complexes were obtained as a mixture of two diastereomers differing only in the metal configuration (R\textsubscript{Os} or S\textsubscript{Os}). The isolation of diastereomerically pure complexes was accomplished by a crystallization method (Scheme 1). Thus, chiral-at-Os\textsuperscript{II} iminopyridine complexes 1, 2, 3, and 4 were isolated as single crystals grown overnight at 277 K from a concentrated methanol solution. Unfortunately, the second diastereomer expected from each reaction could not be isolated as a pure compound although its formation was confirmed in the case of compound 3. All four pure chiral Os\textsuperscript{II} iminopyridine complexes were characterized by CHN analysis, X-ray diffraction, EI\textsuperscript{+} MS, \textsuperscript{1}H NMR and circular dichroism (CD) spectroscopy and their stability in aqueous solution was confirmed before screening for the anticancer activity.

**X-ray diffraction:** The molecular structures of the Os\textsuperscript{II} arene iminopyridine complexes 1, 2, 3, and 4 were established by X-ray crystallography. Only one pure diastereomer was ob-
Os(1) complexes crystallized in the same monoclinic space group: P2₁. The complexes adopt the expected pseudo-octahedral “piano-stool” geometry with the osmium center bound to the arene ligand through η⁶ bonding (Os–arene centroid 1.682–1.695 Å). Additionally, Os(1) is bound to a chloride (2.3892(7)–2.3913(8) Å) or iodide (2.7068(6)–2.7078(4) Å) and two nitrogen atoms (2.074(5)–2.124(9) Å) of the chelating ligand through σ bonds, these ligands constitute the three-legged structure of the “piano stool”. All the bond lengths and angles are in agreement with analogous osmium complexes previously reported.[46]

Cahn–Ingold–Prelog priority rules (CIP system) cannot be applied directly to pseudo-four-coordinate organometallic chiral-at-metal arene complexes. Therefore, to assign the chirality in the R and S convention for these OsⅡ arene complexes, the modified CIP rules for organometallic arene complexes suggested by Tiouflet et al.[47] and Stanley and Baird[48] were used; the p-cymene arene (η⁶-C₆) was considered as a pseudo-atom with atomic weight 72. We defined the priority sequence of ligands attached to the OsⅡ center as follows: NS₃ > Cl > N (imine) > N (pyridine) or I > η⁶-C₆ > N (imine) > N (pyridine). According to the sequence rule of the R/S system, the configurations of the OsⅡ centers in these four chiral osmium arene iminopyridine complexes are: 1 = S Os Os, 2 = S Os, 3 = R Os, and 4 = R Os. Therefore, the retention of chirality at osmium between each chloride complex and its iodo analogue is just a consequence of the change in the priority sequence, as an inversion of configuration at the metal center is observed in the crystal structures (Figure 1A–D).

The four complexes can be divided into two enantiomeric pairs according to the different monodentate ligand coordinated to osmium (chloride or iodide): (S₆S₆)-[Os(η⁶-p-cym)(ImPyMe)Cl]PF₆ (1) and (R₆R₆)-[Os(η⁶-p-cym)-(ImPyMe)Cl]PF₆ (3), (S₆S₆)-[Os(η⁶-p-cym)(ImPyMe)I]PF₆ (2) and (R₆R₆)-[Os(η⁶-p-cym)(ImPyMe)I]PF₆ (4). The comparison between the crystal structures of both pairs of complexes showed no significant differences in their bond lengths and angles around the osmium center.

---

Table 1. Selected bond lengths [Å] and angles [°] for complexes 1 and 3.

<table>
<thead>
<tr>
<th></th>
<th>1 (S₆S₆)[a]</th>
<th>3 (R₆R₆)[b]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Os(1)–N(101) [Å]</td>
<td>2.082(3)</td>
<td>2.086(2)</td>
</tr>
<tr>
<td>Os(1)–N(108) [Å]</td>
<td>2.084(2)</td>
<td>2.086(2)</td>
</tr>
<tr>
<td>Os(1)–arene centroid [Å]</td>
<td>1.685</td>
<td>1.682</td>
</tr>
<tr>
<td>Os(1)–Cl(1) [Å]</td>
<td>2.391(8)</td>
<td>2.389(7)</td>
</tr>
<tr>
<td>N(101)-Os(1)-N(108) [°]</td>
<td>76.61(10)</td>
<td>76.43(9)</td>
</tr>
</tbody>
</table>

[a] Non-classical hydrogen-bond interactions for complex 1: C102–H10A⋯F12; 2.48 Å [x, y, 1+z]; C105–H10D⋯F14; 2.44 Å [1+x, y, 1+z]; C108–H10F⋯F13; 2.37 Å; C202–H20B⋯F15; 2.40 Å; C205–H20D⋯F14; 2.43 Å [x, y, 1+z].

[b] Non-classical hydro-bond interactions for complex 3: C102–H10A⋯F12; 2.48 Å [x, y, 1+z]; C105–H10D⋯F14; 2.44 Å [1+x, y, 1+z]; C109–H10F⋯F13; 2.38 Å; C202–H20B⋯F15; 2.39 Å; C205–H20D⋯F14; 2.43 Å [x, y, 1+z].

---

Table 2. Selected bond lengths [Å] and angles [°] for complexes 2 and 4.

<table>
<thead>
<tr>
<th></th>
<th>2 (S₆S₆)[a]</th>
<th>4 (R₆R₆)[b]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Os(1)–N(1) [Å]</td>
<td>2.084(6)</td>
<td>2.090(4)</td>
</tr>
<tr>
<td>Os(1)–N(8) [Å]</td>
<td>2.090(7)</td>
<td>2.074(5)</td>
</tr>
<tr>
<td>Os(1)–arene centroid [Å]</td>
<td>1.689</td>
<td>1.695</td>
</tr>
<tr>
<td>Os(1)–I(1) [Å]</td>
<td>2.7068(6)</td>
<td>2.7078(4)</td>
</tr>
<tr>
<td>N(1)-Os(1)-N(8) [°]</td>
<td>75.9(3)</td>
<td>76.17(17)</td>
</tr>
</tbody>
</table>

[a] Non-classical hydrogen-bond interactions for complex 2: C4–H4A⋯F12; 2.37 Å [1+x, y, z]; C7–H7A⋯F13A; 2.30 Å [1+x, y, z].

[b] Non-classical hydrogen-bond interactions for complex 4: C4–H4A⋯F12; 2.37 Å [1+x, y, z]; C7–H7A⋯F13A; 2.31 Å [1+x, y, 1+z].

---

Figure 1. X-ray crystal structures of 1 (A), 2 (C), 3 (B), and 4 (D). Thermal ellipsoids are shown at 50% probability. The hydrogen atoms and counterion have been omitted for clarity.
**Table 3. X-ray crystallographic data and structure refinement for complexes 1, 3 and 2, 4.**

<table>
<thead>
<tr>
<th>Formula</th>
<th>1 (S0s,S0)</th>
<th>3 (R0s,R0)</th>
<th>2 (S0s,S0)</th>
<th>4 (R0s,R0)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C15H16ClF4N2OsP</td>
<td>C15H16ClF4N2OsP</td>
<td>C15H16ClF4N2OsP</td>
<td>C15H16ClF4N2OsP</td>
<td></td>
</tr>
<tr>
<td>M1</td>
<td>715.1</td>
<td>715.1</td>
<td>806.55</td>
<td>806.55</td>
</tr>
<tr>
<td>Crystal system</td>
<td>monoclinic</td>
<td>monoclinic</td>
<td>monoclinic</td>
<td>monoclinic</td>
</tr>
<tr>
<td>Crystal size [mm]</td>
<td>0.25 x 0.18 x 0.16</td>
<td>0.24 x 0.20 x 0.20</td>
<td>0.18 x 0.18 x 0.06</td>
<td>0.35 x 0.35 x 0.12</td>
</tr>
<tr>
<td>Space group</td>
<td>P21</td>
<td>P21</td>
<td>P21</td>
<td>P21</td>
</tr>
<tr>
<td>a [Å]</td>
<td>10.19773(12)</td>
<td>10.19210(18)</td>
<td>9.1232(2)</td>
<td>9.1232(2)</td>
</tr>
<tr>
<td>b [Å]</td>
<td>11.79001(13)</td>
<td>11.78829(18)</td>
<td>15.0439(4)</td>
<td>15.0439(4)</td>
</tr>
<tr>
<td>c [Å]</td>
<td>10.99917(13)</td>
<td>10.99531(18)</td>
<td>9.6304(2)</td>
<td>9.6304(2)</td>
</tr>
<tr>
<td>α [°]</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>90</td>
</tr>
<tr>
<td>β [°]</td>
<td>103.0453(12)</td>
<td>103.0937(17)</td>
<td>97.591(3)</td>
<td>97.591(3)</td>
</tr>
<tr>
<td>γ [°]</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>90</td>
</tr>
<tr>
<td>Z</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>μ [mm⁻¹]</td>
<td>5.174</td>
<td>5.181</td>
<td>6.164</td>
<td>6.164</td>
</tr>
<tr>
<td>Reflections collected</td>
<td>27544</td>
<td>11484</td>
<td>13060</td>
<td>12315</td>
</tr>
<tr>
<td>Independent reflections [R(int)]</td>
<td>8081 [0.0360]</td>
<td>6327 [0.0204]</td>
<td>6754 [0.0526]</td>
<td>6765 [0.0294]</td>
</tr>
<tr>
<td>R1, wR2(F &gt; 2σ(F)) [a]</td>
<td>0.0241, 0.0517</td>
<td>0.0184, 0.0387</td>
<td>0.0427, 0.0951</td>
<td>0.0280, 0.0691</td>
</tr>
<tr>
<td>R1, wR2 (all data)[b]</td>
<td>0.070, 0.0526</td>
<td>0.0192, 0.0391</td>
<td>0.0552, 0.0989</td>
<td>0.0288, 0.0698</td>
</tr>
<tr>
<td>GOF [c]</td>
<td>1.017</td>
<td>1.022</td>
<td>1.02</td>
<td>1.03</td>
</tr>
<tr>
<td>Δα max/min [e Å⁻²]</td>
<td>1.217 and −0.796</td>
<td>1.046 and −0.718</td>
<td>2.220 and −1.676</td>
<td>1.904 and −1.058</td>
</tr>
</tbody>
</table>

[a] R1, = Σ |Fo| - |Fc| / Σ |Fo|, [b] wR2 = [Σ w(Fo² - Fc²)² / Σ wFo²]¹/². [c] GOF = [Σ w(Fo² - Fc²)² / n-p]¹/².

**1H NMR spectroscopy:** The 1H NMR spectra of 1, 2, 3, and 4 in [D₆]acetone were recorded at 298 K. Identical 1H NMR data (see Experimental Section) were obtained for both of the chlorido complexes, 1 and 3, as well as for both of the iodo complexes, 2 and 4. These results suggest the molecular structures of each pair of OsIII iminopyridine complexes are mirror images of each other.

To probe the formation of both diastereomers differing at the metal configuration, the first fraction of crystals of 3 was filtered off and the remaining solution was concentrated at reduced pressure to give an orange crystalline product. The 1H NMR data for the orange product showed a diastereomeric mixture of (R0s,R0)- and (S0s,S0)-[Os(n₄-p-cym)(ImpyMe)Cl]PF₆ in approximately 1:1 ratio instead of a single diastereomer (see the Supporting Information, Figure S1). This finding is consistent with a previous report on RuII and OsIII arene salicylaldiminate complexes. There were only small differences between the 1H NMR chemical shifts of both diastereomers, a fact that made it difficult to identify which was the most stable product. For this reason, an initial crystallization step was necessary to obtain pure chiral-at-OsII complexes that separately exhibit different chemical shifts.

**Circular dichroism:** To gain further understanding of the enantiomeric relationships between these pairs of complexes, CD spectra were recorded. This technique measures the differential absorption of left- and right circularly polarized light and is widely used to confirm chiral purity. The CD spectra were recorded for each of the four OsIII iminopyridine complexes in methanol. The chlorido complexes, 1 and 3, and iodo complexes, 2 and 4, gave complementary CD spectra (Figure 2). Complex 1 showed positive Cotton effects at 412 and 288 nm, and negative Cotton effects at 318, 256 and 220 nm. Complex 2 showed positive Cotton effects at 285, 247 and 221 nm, and negative Cotton effects at 450, 313 and 268 nm. Opposite Cotton effects were observed for complexes 1 and 2 and for complexes 3 and 4. Although CD cannot give information on the absolute configuration at the chiral osmium center in the individual complexes in solution, such results confirm that the two molecular structures within the two pairs of OsII iminopyridine complexes are mirror images.

**Stability in aqueous solution:** Although chiral metal centers are usually stable in the solid state at ambient and physiological temperatures, they can behave differently in solutions in which epimerization can occur at ambient temperature with a half-life (t½) less than 24 h. The configurational stability of the metal center in organometallic complexes in solution may depend on the li-
gands around the metal,[51–53] for example, early work on the RuII arene iodido complexes [Ru(η4-p-cym)(LL+)I] (LL+ = (S,R)-(-)-dimethyl(1-phenylethyl)amine) showed that they were more configurationally labile compared with their chlorido analogues.[54] However, there are no reports on the analogous OsIII arene complexes. In general, epimerization occurs in solvents such as acetone, methanol, CH3Cl, or CHCl3 giving rise to the thermodynamic product as the major epimer in solution. Nevertheless, diastereomeric complexes have been shown to be stereochemically stable in hydrocarbon-based solvents.[55]

The configurational stability of OsII arene complexes that are designed as anticancer agents is of particular interest. Each of the four OsIII arene iodido complexes was dissolved in 10% CD3OD/90% D2O phosphate buffer (pH* 7.4), and 1H NMR spectra were recorded before and after incubation for 24 h at 310 K. The two iodido complexes, 2 and 4, showed good stability with no change in the 1H NMR spectra after the incubation period. In contrast, the 1H NMR spectra for both chlorido complexes, 1 and 3, showed new peaks, which may correspond to epimerization or aquation products (see the Supporting Information, Figure S2). When complexes 1 and 3 were incubated at 310 K in the presence of a high molar excess (1000-fold) of sodium chloride (to suppress aquation) and the 1H NMR spectra recorded, no new peaks appeared indicating that the aforementioned new resonances correspond to aquation products and that these complexes are stable towards epimerization. The possibility of substitution of iodide by chloride was investigated for the two iodido complexes, 2 and 4. The NMR data showed no substitution of iodide by chloride for either 2 or 4 (100 µM) at high concentrations of Cl– (5000 mol equiv, 500 mM) (see the Supporting Information, Figure S2).

Anticancer activity: Iminopyridine- and azopyridine-containing complexes[56–57] with Ru and Os centers can exhibit potent anticancer activity.[58–62] In particular, an OsII arene azopyridine complex is active in vivo.[56] Therefore, the anticancer activity of the four OsII arene iminopyridine complexes 1–4 were studied in the human ovarian cancer cell line A2780. After 24 h incubation followed by 72 h recovery time, the two chlorido Os complexes, 1 and 3, showed moderate anticancer activity, with IC50 values of approximately 20 µM, similar to the value obtained for the mixture of (R,R,R,R)- and (S,S,R,R)-[Os(η4-p-cym)(ImpyMe)Cl]PF6 (Table 4) and significantly higher than that of cisplatin (2 µM). On the other hand, the IC50 values of the two iodido osmium complexes, 2 and 4, are in the same range as that of cisplatin (Table 4). These two iodido complexes were further screened in the NCI (National Cancer Institute) panel of 60 human tumor cell lines at five concentrations[63,64] and both 2 and 4 showed potent anticancer activities with mean IC50 values of 9.55 and 7.58 µM, respectively. In contrast, the two chlorido complexes, 1 and 3, were not sufficiently active when tested against the NCI 60-cell-line panel (mean IC50 values > 10 µM) to warrant 5-dose testing. The mean growth inhibition parameters determined in the NCI screen of MG-MID (full-panel mean-graph midpoint) values of IC50, the concentration that inhibits cell growth by 50%, TGI, the concentration that inhibits cell growth by 100%, and LC50 (the concentration that kills 50% of the original cells) are listed in Table 5. The details for each cell line and the values of IC50, TGI, and LC50 are shown in Table S1 (see the Supporting Information). Similar to cisplatin, the two OsIII iodido complexes showed a broad range of anticancer activities towards different cell lines, with IC50 values ranging from nanomolar to micromolar (530 nM to > 100 µM).

<table>
<thead>
<tr>
<th>Complex</th>
<th>IC50 [µM][b]</th>
<th>TGI [µM][c]</th>
<th>LC50 [µM][d]</th>
</tr>
</thead>
<tbody>
<tr>
<td>(S,R,R,R)-[Os(η4-p-cym)(ImpyMe)Cl]PF6 (2000 µM)</td>
<td>7.58</td>
<td>53.7</td>
<td>89.1</td>
</tr>
<tr>
<td>(S,R,S,R)-[Os(η4-p-cym)(ImpyMe)Cl]PF6 (4000 µM)</td>
<td>3.58</td>
<td>53.7</td>
<td>89.1</td>
</tr>
</tbody>
</table>

[a] NCI codes for complex 2: NSC: D-758116/1 and 4: NSC: D-758118/1. [b] IC50 is the concentration that inhibits cell growth by 50%. [c] TGI is the concentration that inhibits cell growth by 100%. [d] LC50 is the concentration that kills 50% of the original cells. [e] Cisplatin data from NCI/DTP screening: March 2012, 48 h incubation time.[10]

Catalysis of imine reduction: Organometallic ruthenium,[40] rhodium,[65] and iridium[66] complexes have been found to act as transfer-hydrogenation catalysts for the asymmetric reduction of ketones and imines. However, there are very few reports of the catalytic activity of osmium complexes,[43,44] especially for OsIII arene complexes.[67] The possible catalytic activity of the two OsII arene iminopyridine iodido complexes, 2 and 4, for cyclic imine (6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline) reduction was therefore evaluated. We observed a reasonable conversion (20–76%) and low ee value (20–22%) for reactions with both OsII complexes in less than 24 h (see the Supporting Information, Figure S4).[68] demonstrating potential of the complexes as transfer-hydrogenation catalysts. This appears to be the first report of this type of OsIII arene iminopyridine iodido complex acting as a catalyst in transfer hydrogenation. Although the asymmetric reduction of imines by RuIII complexes has been studied in some detail, the mechanism of the reaction, in contrast to ketone reduction, is unclear. A recent report
suggested that the reduction takes place through an “open” transition state in which binding to the N–H of the complex (typical for ketone reduction) is not required. This is supported by experiments conducted on stoichiometric reduction systems and also by molecular modeling. A similar mode of reduction has been proposed for enzyme-bound imine reductions. The proposed mechanism retains the CH–π interaction that has been proposed for similar systems, although it is not clear whether this is operating in the current system.

Discussion

Crystal structures: Only one chiral configuration at the OsII center was observed in the X-ray crystal structures of chiral-at-OsII iminopyridine complexes 1, 2, 3, and 4, a fact that is consistent with the indication from the 1H NMR data. Thus, the use of two enantiomeric ligands in this work for the crystallization of pure diastereomers allowed us to successfully isolate two pairs of enantiomers (1, 3 and 2, 4, respectively). These results differ markedly from our previous findings on the OsII iminopyridine complex [Os(η5-p-cym)-Impy-OH]PF6, whose X-ray crystal structure revealed a racemic mixture of enantiomers, (S)-[Os(η5-p-cym)-(Impy-OH)]PF6 and (R)-[Os(η5-p-cym)-(Impy-OH)]PF6.

Chiral resolution of the second set of enantiomers in solution was hampered by their low solubility. The assignment of chirality for the two pairs of osmium diastereomers 1/3 and 2/4 is consistent with their complementary CD spectra (Figure 2). It is apparent that the absolute stereochemical arrangements of the ligands around the osmium center in the complexes with the same chelating ligand 1 and 2 (chelating ligand = (S)-ImpyMe), 3 and 4 (chelating ligand = (R)-ImpyMe) are similar. These complexes do not exhibit the intramolecular “β-phenyl effect” found in previously reported organometallic arene complexes derived from similar chiral ligands. This stabilizing effect consists of an edge-to-face CH–π attractive interaction between the arene hydrogen atoms and a phenyl group from the optical active ligand, consequently giving rise to the thermodynamic product. Most of the published examples of diastereomeric RuII and OsII arene complexes showing the “β-phenyl effect” are neutral complexes or contain different counterions (for example, ClO4−, Cl−, PF6−).

The crystal structures of compounds 1–4 show the phenyl substituent from the ImpyMe ligand orientated downwards in order to avoid steric interactions with the p-cymene. A structural difference found between the chlorido and iodoido complexes is the spatial arrangement of the methyl substituent from the ImpyMe ligand with respect to the monodentate ligand. The methyl group is directed towards the halide ligand in the chlorido complexes, 1 and 3, but it points in the opposite direction in the iodoido analogues, 2 and 4, probably owing to steric repulsion by the bulky coordinated iodoide. It is notable that in the chlorido complexes, an intramolecular non-classical *C–H···F bond interaction between the PF6− counterion and the hydrogen atom attached to the chiral carbon atom of the iminopyridine ligand is observed, whereas in the case of the iodoido analogues this interaction occurs with the imine hydrogen. Additionally the PF6− anion hydrogen bonds to the p-cymene ligand and the pyridine ring of the ImpyMe ligand (Tables 1 and 2).

Regarding the thermodynamic/kinetic origin of the crystallized products, equilibration between the diastereomers at ambient temperature can be a fast process in which the thermodynamic product is obtained as the major epimer in solution. The equilibrium constant and configurational lability at the metal center depend on the temperature and the solvent, and some ruthenium arene complexes have a stable metal configuration even at high temperatures. Several 1H NMR kinetic studies carried out by Brunner et al. on configurationally labile RuII and OsII half-sandwich diastereomers concluded that at low temperatures (193–195 K) the major epimer (thermodynamic product) exists as the only compound in solution. An increase in temperature (223–294 K) favors the formation of the kinetic diastereomer, the percentage of which is higher at higher temperatures. Frequently the crystallization of these diastereomeric mixtures in solution gives rise to single crystals that contain only the less soluble diastereomer.

Taking all this into account, complexes 1, 2, 3, and 4 can be considered as the kinetic products of the reaction as well as the less soluble epimers at the temperature at which their crystallization from methanol took place (277 K). Few examples of OsII half-sandwich complexes crystallized as diastereomerically pure compounds have been reported.

Circular dichroism: The CD spectra of the pairs of enantiomers (Sα,Sβ)-[Os(η5-p-cym)-(ImpyMe)Cl]PF6 (1) and (Rα,Rβ)-[Os(η5-p-cym)-(ImpyMe)Cl]PF6 (3), (Sα,Sβ)-[Os(η5-p-cym)-(ImpyMe)I]PF6 (2) and (Rα,Rβ)-[Os(η5-p-cym)-(ImpyMe)I]PF6 (4) showed several absorption bands with maximum intensities in the range 220–350 nm. A shoulder around 340 nm is also observed in spectra of the chlorido compounds, 1 and 3. These bands may be attributable to π → π* and n → n* transitions of the coordinated chiral iminopyridine ligand. Additionally, both pairs of enantiomers displayed two broad bands of lower intensity between 360–550 nm due to metal-based transitions. The opposite Cotton effects observed for 1 and 2 compared to 3 and 4, respectively, Figure 2, indicate that they are two pairs of mirror-image complexes.

Aqueous configuration stability: There was no epimerization at the OsII center during a 24 h incubation at 310 K of both the chlorido, 1 and 3, and iodoido, 2 and 4, diastereomeric OsII iminopyridine arene complexes. This suggests that they are stable enough to allow further investigations of the effects of chirality of the osmium metal center on biological activity. As aquation and nucleophilic substitution of the metal–halide bond are involved in the general mechanism associated with DNA binding for RuII and OsII arene anticancer complexes, the
mechanism of anticancer activity of these inert Os\textsuperscript{II} arene iminopyridine iodido complexes is unlikely to involve DNA as a target in contrast to some previously reported Os\textsuperscript{II} arene complexes.\textsuperscript{[74]}

**Density functional theory calculations:** It is apparent that the synthetic route used for all the four osmium arene iminopyridine halido complexes can give rise to both \( R \) and \( S \) configurations at Os. To compare the thermodynamic stabilities of the diastereomers, density functional theory (DFT) calculations were performed to optimize the geometry and calculate energies. These calculations were run at the B3LYP/LANL2DZ/6-31G** level in gas phase by using Gaussian 03.

For the two osmium chlorido complexes, the sequence of thermodynamic stability was: \( 3 \) (\( R_{\text{Os},C} > 1 \) (\( S_{\text{Os},C}) > (S_{\text{Os},R}) = (R_{\text{Os},S}) \) configuration. According to computational results, the \( 1 \) configuration is only 0.043 kJ mol\(^{-1}\) less stable than \( 3 \), whereas the (\( R_{\text{Os},S}) \) and (\( S_{\text{Os},R}) \) configurations are similar and 6.93 kJ mol\(^{-1}\) less stable than \( 1 \). For the two osmium iodido complexes, the sequence of thermodynamic stability follows the order: (\( S_{\text{Os},R}) \) configuration > (\( R_{\text{Os},S}) \) configuration > (\( 2 \) (\( S_{\text{Os},R}) = (R_{\text{Os},S}) \). According to the calculated energies, the (\( R_{\text{Os},S}) \) configuration is only 0.002 kJ mol\(^{-1}\) less stable than the (\( S_{\text{Os},R}) \) configuration, whereas \( 2 \) and \( 4 \) are 10.06 kJ mol\(^{-1}\) less stable than the (\( R_{\text{Os},S}) \) configuration. Although the differences in energy are small, the computational results indicate that \( 1 \) and \( 3 \) are the thermodynamically favored isomers, while \( 2 \) and \( 4 \) are not thermodynamically favored isomers in terms of the chirality at osmium. Their separation may arise from solubility differences between the epimers.

**Anticancer activity:** Further analysis of the in vitro anticancer efficacy of complexes \( 2 \) and \( 4 \) by the NCI revealed a broad spectrum of activity with promising selectivity towards melanoma and breast cancer cell lines. The breast cell line MDA-MB-468 showed particularly promising results with IC\textsubscript{50} values in the sub-micromolar range (703 nM for \( 2 \) and 530 nM for \( 4 \)). Also notable is the low selectivity of \( 2 \) and \( 4 \) for renal cancer cell lines (Figure 3), with IC\textsubscript{50} \( > 100 \) \( \mu \)M for most of the renal cell lines in the NCI-60 screening.

The COMPARE algorithm is an open tool developed by the NCI to quantify directly the similarity in cell line sensitivity between compounds.\textsuperscript{[84]} Each NCI-60 mean graph is taken as a fingerprint for the compound and is quantitative-ly compared to mean graphs for other compounds, producing a Pearson’s correlation coefficient (PCC) between –1 and 1 as a similarity measure. This method has been used successfully to predict mechanisms of action of emerging drugs by highlighting similarity in mean graph fingerprints to drugs of known mechanism in the NCI databases.\textsuperscript{[70]}

A single analysis using the COMPARE algorithm for each complex against the NCI/DTP (Developmental Therapeutics Program) Standard Agents Database, housing 171 known anticancer compounds, was conducted.\textsuperscript{[70]} The results provide preliminary indications of a possible mechanism of action based on a correlation of the NCI 60-cell-line patterns of sensitivity.\textsuperscript{[77]} The three endpoints (IC\textsubscript{50}, TGI, and LC\textsubscript{50}) were used in the algorithm and those agents in the database with the highest PCC values were analyzed (Tables S2–S4). The highest PCC value for each endpoint for both complexes \( 2 \) and \( 4 \) was for vinblastine sulfate, an inhibitor of tubulin polymerization. The quantitative analysis of the selectivity patterns between complexes \( 2 \) and \( 4 \) gave PCC values of 0.973 (IC\textsubscript{50}), 0.969 (TGI), and 0.976 (LC\textsubscript{50}) for different endpoints, indicating that \( 2 \) and \( 4 \) may share high similarity in their mechanisms. This is demonstrated in the mean graphs in Figure 3, where the pattern of sensitivity is
almost identical. We assessed whether cisplatin showed a significant correlation to either 2 or 4, and found that this comparison produced a PCC value of −0.298. This negative value highlights that cisplatin has a distinctly different pattern of selectivity and suggests a different mechanism of action from complexes 2 and 4 (Table 6).

The prevention of polymerization of microtubules in vitro was investigated by assessing whether OsII complexes 2 and 4 interact directly with tubulin. Relative concentrations of OsII complexes (10 μM) were selected according to the IC50 values from the cell tests. Purified, unpolymerized tubulin was incubated with OsII compounds and the polymerization process monitored at 310 K for 60 min. Taxol and colchicines were used as positive controls for polymerization facilitation and inhibition, respectively.[79] Under these conditions, no inhibition of polymerization by OsII complexes was observed (see the Supporting Information, Figure S3), a fact that indicated that the mechanism of action does not involve direct interaction with tubulin.

**Table 6.** COMPARE analysis showing the highest correlations for complexes 2 and 4 with known anticancer drugs, as indicated by their PCC (Pearson's correlation coefficient) values.

<table>
<thead>
<tr>
<th>Complex</th>
<th>PCC</th>
<th>Name</th>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>(S,R,S,R)-[Os(η⁵-cym)(ImpyMe)][PF₆] (2)</td>
<td>0.743</td>
<td>vinblastine sulfate</td>
<td>antimitrotubule agent</td>
</tr>
<tr>
<td>(R,R,R,R)-[Os(η⁵-cym)(ImpyMe)][PF₆] (4)</td>
<td>0.754</td>
<td>vinblastine sulfate</td>
<td>antimitrotubule agent</td>
</tr>
</tbody>
</table>

**Conclusion**

There are few reported studies of isolated organometallic complexes with chirally pure OsII centers. In this work, through incorporation of an additional chiral center into a chelated iminopyridine ligand, we have separated four chiral OsII arene anticancer complexes by fractional crystallization: two iodido complexes, (S,R,S,R)-[Os(η⁵-cym)(ImpyMe)][PF₆] (2), containing (S)-ImpyMe: N-(2-pyridylmethylene)-(S)-1-phenylethylamine, and (R,R,R,R)-[Os(η⁵-cym)(ImpyMe)][PF₆] (4), containing (R)-ImpyMe: N-(2-pyridylmethylene)-(R)-1-phenylethylamine, and the two chloro derivatives (S,R,S,R)-[Os(η⁵-cym)(ImpyMe)Cl][PF₆] (1) and (R,R,R,R)-[Os(η⁵-cym)(ImpyMe)Cl][PF₆] (3). Their X-ray crystal structures and CD spectra verified their mirror image configurations. Interestingly, the two iodido OsII arene complexes, 2 and 4, showed more promising anticancer activity against A2780 human ovarian cancer cell line and the NCI 60-cell-line screening compared with the two chlorido OsII arene complexes, 1 and 3. Quantitative analysis of the NCI 60-cell-line screen using the COMPARE algorithm showed that the two potent iodido complexes have surprisingly similar selectivity patterns to one another and to an anti-microtubule drug, vinblastine sulfate. However, no direct effect towards tubulin polymerization was found for 2 and 4, a fact that may indicate a different or indirect mechanism of action. Other than anticancer activity, 2 and 4 also demonstrated potential as hydrogenation transfer catalysts for imine reduction.

**Experimental Section**

**Starting materials:** OsCl₃·3H₂O was purchased from Alfa-Aesar. Ethanol and methanol were dried over MgSO₄ or anhydrous quality was used (Aldrich). All other reagents were obtained from commercial suppliers and used as received. The preparations of the starting materials [(Os(η⁵-cym)Cl)₂] and [(Os(η⁵-cym)I)₂] have been previously reported.[79] The synthesis and purification of the chiral pure iminopyridine ligands, (S)-ImpyMe: N-(2-pyridylmethylene)-(S)-1-phenylethylamine, and (R)-ImpyMe: N-(2-pyridylmethylene)-(R)-1-phenylethylamine, were carried out according to the literature method.[58] The A2780 human ovarian cancer cell line was purchased from European Collection of Animal Cell Cultures (Salisbury, UK). RPMI-1640 media and trypsin were purchased from Invitrogen, bovine serum from Biosera, penicillin, streptomycin, trichloroacetic acid (TCA), and sulforhodamine B (SRB) from Sigma–Aldrich, and tris(hydroxymethyl)aminoethane from Formedium.

**Syntheses and characterization:** All the OsII compounds were synthesized and crystallized by a general method that is described for compound 1. Single crystals suitable for X-ray diffraction were obtained for all these compounds and were used for all the chemical and biological tests. [(S,R,S,R)-Os(η⁵-cym)(ImpyMe)][PF₆] (1): [(Os(η⁵-cym)Cl)₂] (50.0 mg, 0.063 mmol) was dissolved in methanol (20 mL) at 313 K. (S)-ImpyMe (26.9 mg, 0.12 mmol) in methanol (10 mL) was added drop-wise. The solution changed color from orange to red immediately, and was stirred at ambient temperature (ca. 293 K) for 2 h. Ammonium hexafluoroacetate (41.2 mg, 0.24 mmol) was added. Then the solution was left in a fridge at 277 K for 24 h. Dark brown colored single crystals were obtained and were collected by filtration, washed with cold ethanol and diethyl ether, and dried under vacuum. Yield (single crystals): 54.0 mg (58.7%).

1H NMR (400 MHz, (CD₃)₂CO): δ = 9.59 (d, J = 6 Hz, 1H), 9.32 (s, 1H), 8.47 (d, J = 8 Hz, 1H), 8.32 (t, J = 6 Hz, 1H), 7.73 (t, J = 6 Hz, 2H), 7.62–7.55 (m, 3H), 6.55 (d, J = 6 Hz, 1H), 6.16 (d, J = 6 Hz, 2H), 6.08 (qd, J = 6 Hz, 1H), 2.65 (s, 3H), 2.54–2.42 (m, 1H), 2.38 (s, 6H), 1.93 (d, J = 6 Hz, 3H), 1.11 (d, J = 7 Hz, 3H), 0.89 ppm (d, J = 7 Hz, 3H); ESI-MS: m/z cale for [C₆H₆CIF₂Os]: 571.2 [M⁺]; found 571.1; elemental analysis calcd (%) for C₆H₆CIF₂Os: C 40.31, H 3.87, N 3.90; found: C 40.30, H 3.87, N 3.90; CD (CH₃OH): λmax (A): 412 (–42), 318 (–58), 288 (–64), 256 (–78), 220 nm (–100 mol-cm⁻¹). The brown single crystals of 1 were suitable for study by X-ray diffraction.

[(R,R,R,R)-Os(η⁵-cym)(ImpyMe)][PF₆] (2): Prepared by following the same method as for complex 1. Yield (single crystals): 28.9 mg (35.8%).

1H NMR (400 MHz, (CD₃)₂CO): δ = 9.57 (d, J = 6 Hz, 1H), 9.43 (s, 1H), 8.48 (d, J = 8 Hz, 1H), 8.25 (t, J = 6 Hz, 1H), 7.77 (t, J = 6 Hz, 2H), 7.52–7.48 (m, 3H), 6.49 (d, J = 6 Hz, 1H), 6.26 (d, J = 6 Hz, 1H), 6.08 (qd, J = 6 Hz, 1H), 6.04 (d, J = 6 Hz, 1H), 5.83 (d, J = 6 Hz, 1H), 2.84 (s, 3H), 2.67–2.60 (m, 1H), 2.65 (s, 6H), 2.13 (d, J = 6 Hz, 3H), 0.10 ppm (d, J = 7 Hz, 3H); ESI-MS: m/z cale for [C₆H₆CIF₂Os]: 663.1 [M⁺]; found 663.0. elemental analysis calcd (%) for C₆H₆CIF₂Os: C 37.54, H 3.50, N 3.47; found: C 37.56, H 3.53, N 3.36; CD (CH₃OH): λmax (A): 450 (–99), 313 (–57), 285 (–24), 268 (–30), 247 (–42), 221 nm (–51 mol-cm⁻¹). The brown single crystals grown from a cooled methanol solution (277 K) were suitable for X-ray diffraction studies.
Orange single crystals suitable for X-ray crystallography were obtained after cooling a portion of the methanol solution at 277 K. 

\( \text{R}^2_1\text{R}^2_3\text{c} \cdot \text{Os(n}^2\text{-py})\text{(MePyMe)}\text{PF}_6 \) (4): Prepared by following the same method as for complex 1. Yield (single crystals): 25.2 mg (35.6%); 

\( ^{1}H\text{ NMR (400 MHz, CD}_3\text{CO}: d = 9.57 (d, J = 6 Hz, 1 H), 9.43 (s, 1 H), 8.34 (d, J = 8 Hz, 1 H), 8.25 (t, J = 6 Hz, 1 H), 7.77 (t, J = 6 Hz, 2 H), 7.52–7.48 (m, 3 H), 6.49 (d, J = 6 Hz, 1 H), 6.26 (d, J = 6 Hz, 1 H), 6.08 (qd, J = 6, 8 Hz, 1 H), 6.04 (d, J = 6 Hz, 1 H), 5.83 (d, J = 6 Hz, 1 H), 2.84 (s, 6H), 2.13 (d, J = 7 Hz, 3H), 1.10 (d, J = 7 Hz, 3H), 0.91 ppm (d, J = 7 Hz, 3H); ESI-MS: m/z calculated for \text{C}_24\text{H}_28\text{F}_6\text{IN}_2\text{OsP}: 663.1 [M]+; found 663.0; elemental analysis calculated (%) for \text{C}_{35.74}\text{H}_{3.50}\text{N}_{3.47}: found \text{C}_{35.63}\text{H}_{3.47}\text{N}_{3.33}; ESI-MS: m/z calculated for C\text{H}_3\text{I}\text{N}_2\text{OsH}_2\text{O}: 166.9 [M]+; found 167.0; ESI-MS: m/z calculated for C\text{H}_2\text{I}\text{N}_2\text{O}: 145.6 [M]+; found 145.5. 

Data evaluation, mean graph analysis, and COMPARE analysis: Anti-proliferative efficacies of test compounds in both assays were described by inhibitory concentrations (IC\text{50} values), reflecting concentration-dependent cytotoxicity. Complexes 2 and 4 were selected for study in the human 60-cell-line panel of the Developmental Therapeutics Program (DTP) of the National Cancer Institute (NCI), a panel that includes nine tumor-type subpanels. The cells were treated for 48 h at five concentrations ranging from 0.01 to 100 \( \mu \text{M} \). Three endpoints were calculated: IC\text{50} (the concentration that inhibits cell growth by 50%); TGI (the concentration that inhibits cell growth by 100%); LC\text{50} (the concentration that kills 50% of the original cells); MG-MID (full-panel mean-graph midpoint). The MG-MID value therefore represents an antiproliferative fingerprint of a compound. The COMPARE analysis was carried out using the NCI/DTP Standards Agents database, a collection of 171 known anticancer compounds, to provide preliminary indications on a possible mechanism of action. 

**Instrumentation**

**NMR spectroscopy:** \( ^{1}H\text{ NMR spectra were acquired in 5 mm NMR tubes at 298 K on either Bruker DPX-400, Bruker DRX-500, or Bruker AV II 700 spectrometers.} \( ^{1}H\text{ NMR chemical shifts were referenced to D}_{4}\text{acetone (2.09 ppm).} All data processing was carried out using MestReC or TOPSPIN version 2.0 (Bruker U.K. Ltd.). 

**Electrospray ionisation mass spectrometry (ESI-MS):** Spectra were obtained by preparing the samples in 50% CH\text{CN} and 50% H\text{2O} (v/v) and infusing into the mass spectrometer (Varian 4000). The mass spectra were recorded with a scan range of m/z 200–1000 for positive ions. 

**Elemental analysis:** Elemental analysis (carbon, hydrogen, and nitrogen) was carried out through Warwick Analytical Service using an Exeter analytical elemental analyzer (CE440).

**pH** measurements: pH (pH meter reading from D-O solution without correction for effects of deuterium on glass electrode) values were measured at ambient temperature before the NMR spectra were recorded, using a Corning 240 pH meter equipped with a micro-combination electrode calibrated with Aldrich buffer solutions at pH 4, 7, and 10. 

**X-ray crystallography:** X-ray diffraction data for 1, 2, 3, and 4 were obtained on an Oxford Diffraction Gemini four-circle system with a Ruby CCD area detector using Mo\text{K}\alpha radiation. Absorption corrections were applied by using ABSPACK. The crystals were mounted in oil and held at 100(2) K with the Oxford Cryosystem Cryostream Cobra. The structures were solved by direct methods using SHELXS (TREF) with additional light atoms found by Fourier method and refined against \( F^2 \) using SHELXL. Hydrogen atoms were added at calculated positions and refined using a riding model with freely rotating methyl groups. Anisotropic displacement parameters were used for all non-H atoms; H atoms were given isotropic displacement parameters equal to 1.2 (or 1.5 for methyl hydrogen atoms) times the equivalent isotropic displacement parameter of the atom to which the H atom is attached. The graphics for the crystal structures were made with Mercury 2.4. CCDC-941759 (1), 941760 (2), 941761 (3), and 941762 (4) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.a- c.uk/data_request/cif.

**Cell cultures:** A2780 human ovarian cancer cell lines (ECACC, Salisbury, UK) were cultured in RPMI 1640 cell culture medium supplemented with 1 mm sodium pyruvate, 2 mm l-glutamine, and 10% fetal bovine serum.

**Circular dichroism:** Circular dichroism spectra of 1, 2, 3, and 4 were recorded on a J-815 circular dichroism spectropolarimeter (Jasco, UK) at ambient temperature (ca. 293 K). The spectra were determined for all the samples at a concentration of 1 mm in methanol using a quartz cuvette of 0.1 cm path length, scan speed of 200 nm/min, 1 nm band width, 0.2 nm data pitch, and 0.5 s of response time.

**Methods**

**Aquatino:** Solutions of 1, 2, 3, or 4 in 10% CD\text{OD}/90% D\text{2O} phosphate buffer \((\text{v/v})\) were prepared by dissolution in CD\text{OD} followed by a dilution with D\text{2O} phosphate buffer \((\text{pH}=7.2). \) NMR spectra were recorded after 24 h of incubation at 310 K. The extent of aquation was determined from \( ^{1}H\text{ NMR peak integrals.} \)

**Determination of A2780 IC\text{50} values:** The method was similar to that previously described.

**NCl 60-cell-line screen:** The cells were treated for 48 h at five concentrations ranging from 0.01 to 100 \( \mu \text{M} \). Three endpoints were calculated: IC\text{50} (the concentration that inhibits cell growth by 50%); TGI (the concentration that inhibits cell growth by 100%); LC\text{50} (the concentration that kills 50% of the original cells); MG-MID (full-panel mean-graph midpoint). Cisplatin data were from NCI/DTP screening: Oct 2009, 48 h incubation.

**Acknowledgements**

We thank the ERC (grant no. 247450 BIOINCMED), EPSRC, and Science City/EU ERDF/AMW (MaXis mass spectrometer and the X-ray diffractometer) for funding. M.J.R. thanks Fundación Barrié (Spain) for...
Mirror-Image Osmium Complexes with Anticancer Activity

FULL PAPER

Received: June 7, 2013
Published online: September 23, 2013


15209

[82] G. M. Sheldrick, SHELX97 1997, Programs for Crystal Structure Analysis (Release 97 – 92); University of Göttingen, Germany.